Innovations in Care
PREVAIL Phase 3 study in generalized Myasthenia Gravis
Tuesday, October 17, 2023
Noon, ET
Duration: 30 minutes
A study by Alexion to investigate its new complement inhibitor Gefurulimab (ALXN1720) for the treatment of Myasthenia Gravis.
Speakers:
Sanjay Rakhade MD, PhD
Executive Medical Director
Alexion Astra Zeneca Rare Disease Unit
Joachim Scholz, MD
Medical Director Clinical Development and Translational Sciences
Alexion Astra Zeneca Rare Disease
After registering, you will receive a confirmation email containing information about joining the webinar conducted on Zoom. If you have questions or comments, please contact mdapartners@mda.org
If you have questions or comments, contact mdapartners@mdausa.org
This Industry Update Webinar is sponsored by Alexion. MDA is providing this resource as an educational opportunity for the neuromuscular disease community. This program is not sponsored, endorsed, or accredited by MDA.
Find MDA
in your Community
-
Search for Clinical Trials
Learn More
